GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

InterMune Licenses Qualyst's Drug Discovery Technology

  • Intermune signed a multiyear license to use Qualyst's B-Clear® system for its drug discovery programs. 

    B-Clear offers research organizations the ability to generate physiologically-relevant data and enable decision making in areas related to hepatic transport and adverse drug interactions, helping to avoid costly drug development challenges and enabling better prediction of bioavailability, pharmacokinetics, species-specific drug dosing, and candidate selection.

    The system is a sandwich-cultured hepatocyte system for the in vitro assessment and in vivo prediction of critical pharmacokinetic properties, including hepatobiliary disposition, hepatic uptake, hepatic accumulation, biliary clearance, and drug transport.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?